Ocrelizumab-induced acute pancreatitis: case report of an uncommon side effect of multiple sclerosis treatment

Pancreatitis should be considered in ocrelizumab-treated patients presenting with abdominal pain, even when routine risk factors are absent. Early recognition enables appropriate management and contributes to a growing evidence base needed to clarify pathophysiology and refine risk stratification for this uncommon adverse event.